There is ongoing progress in developing vaccines and antivirals for norovirus, which are particularly needed for immunocompromised patients and healthcare workers.
Answers are grounded in this paper and cite their sources.
No licensed norovirus options yet; leaves open translation of promising candidates to practice pending further trials.
Noroviruses are now recognized as the major cause of acute gastroenteritis in the developed world, yet our ability to prevent and control infection is limited. Recent work has highlighted that, while typically an acute infection in the population, immunocompromised patients often experience long-term infections that may last many years. This cohort of patients and those regularly exposed to infectious material, for example, care workers and others, would benefit greatly from the development of a vaccine or antiviral therapy. While a licensed vaccine or antiviral has yet to be developed, work over the past 10 years in this area has intensified and trials with a vaccine candidate have proven promising. Numerous antiviral targets and small molecule inhibitors that have efficacy in cell culture have now been identified; however, further studies in this area are required in order to make these suitable for clinical use.
No takes yet. Share an insight, caveat, or question.
Arias et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: